BOWEL cancer is one of the most common types of cancer diagnosed in the UK. Most of the symptoms are associated with bowel habits, which include changes in the shape of your poo.
Sirtex Medical receives positive recommendation from National Institute for Health and Care Excellence (NICE) for selective internal radiation therapy (SIRT) using SIR-Spheres
WOBURN, Mass., Feb. 26, 2021 /PRNewswire/
Sirtex Medical US Holdings, Inc. ( Sirtex ), a leading manufacturer of targeted cancer therapies, received positive guidance from the National Institute for Health and Care Excellence (NICE) regarding the use of selection internal radiation therapy (SIRT) with SIR-Spheres Y-90 microspheres for the treatment of adults with unresectable advanced hepatocellular carcinoma (HCC).
NICE recommends the use of SIRT using SIR-Spheres in England and Wales as a fully funded and reimbursed option for adult patients with HCC, on the conditions that it is used for people with Child-Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and that the company provides SIR-Spheres according to the commercial arrangement.
UK grants marketing authorisation to “landmark” breast cancer therapy
13
Seagen’s Tukysa
® (tucatinib) was approved in the UK as part of a combination regimen for the treatment of adults with locally advanced or metastatic HER2-positive breast cancer.
® (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2 positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.
“Every year, an estimated 55,000 people are diagnosed with breast cancer in the UK, of which up to one in five are estimated to have HER2 positive tumours,” said Dr Alicia Okines, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, UK. “The authorisation of tucatinib in combination with trastuzumab and capecitabine is a significant step forward for adult patients with advanced, incurable HER2 positive breast cancer. With this authorisation, our patients, including those w
The number of new cancer cases in the country continues to increase annually. Last year alone, over nine hundred new cancer cases were reported. This was shared by Doctor Raden Mas Jeffri bin Raden Mas Ismail, Consultant Medical Oncologist, The Brunei Cancer Centre, TBCC, Pantai Jerudong Specialist Centre in an interview during yesterday morning s Rampai Programme in conjunction with World Cancer Day. Among the frequently occurring cancer are breast cancer, colon cancer and cervical cancer which affect women. Colon cancer, followed by lung cancer and prostate cancer can easily affect male patients.
Doctor Raden Mas Jeffri also explained that patients with the risk of getting cancer are those aged 40 and above. Eventhough last year the country faced the challenge of COVID-19, cancer treatment in the country was able to be carried out well. According to Doctor Raden Mas Jeffri, cancer is the main cause of death in many countries including Brunei Darussalam. The Union for Inte
Dramatic changes seen in delivery of radiotherapy treatments during coronavirus pandemic
Dramatic changes were seen in the delivery of radiotherapy treatments for cancer during the first wave of the coronavirus pandemic in England.
Much shorter radiotherapy courses were delivered, treatments were delayed where it was safe to do so and some increases were seen in order to compensate for reduced surgical capacity.
Experts believe the changes reflect an impressive adaption of services by the NHS, and that the overall impact on cancer outcomes is likely to be modest.
The new research, led by the University of Leeds, with Public Health England and the Royal College of Radiologists, reveals that there was a decrease in radiotherapy treatment courses of 19.9% in April, 6.2% in May, and 11.6% in June 2020, compared with the same months the previous year.